Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
COPD, Dupixent and FDA
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
Dupixent Gets FDA Approval for COPD
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
FDA approves first biologic treatment for COPD
The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD). Dupixent is the first
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,
Sanofi's Dupixent scores double COPD win in US, China
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD -- as has China's National Medical Products Administration (NMPA) which announced its approval the same day. It's the first ever biologic medicine for COPD in either country.
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.
Sanofi, Regeneron get USFDA nod for Dupixent for COPD
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
MedCity News
4d
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
Sanofi
recognizes all revenue from antibodies ... we think there’s a strong rationale for
COPD
as well,” Rowe said.
5d
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Court filing made public
Helene's wake
Walz, Vance VP debate
California gang busted
Golf Hall of Famer dies
OH gov. declares emergency
5 Chinese nationals charged
Ex-detective denied parole
US diagnostic errors study
Strike leads to panic-buying
WW2-era bomb explodes
MA new gun law takes effect
‘Ryan's Hope' actor dies
Dream fire coach Wright
AZ voter registration glitch
Valuation reaches $157B
May face additional charges
AG appeals abortion ruling
Murdaugh's appeal rejected
ABC News layoffs
CA deepfakes law blocked
Sued over inmate call rules
Can't sue Uber over crash
Voyager 2 tool turned off
Factory probed after Helene
Doctor pleads guilty
Feedback